BEGIN:VCALENDAR
VERSION:2.0
PRODID:-//Pharmaconomics//FDA Catalyst Calendar//EN
CALSCALE:GREGORIAN
METHOD:PUBLISH
BEGIN:VEVENT
UID:pharmaconomics-1252@pharmaconomics
DTSTAMP:20260707T033906Z
DTSTART;VALUE=DATE:20250716
DTEND;VALUE=DATE:20250717
SUMMARY:OKYO Phase 2 — urcosimod
DESCRIPTION:Phase 2 trial results for urcosimod in neuropathic corneal pain (NCP) are due Jul 16\, 2025. A clean hit validates the program\; a miss can gap the stock down hard.\n\nPrimary source: https://www.sec.gov/Archives/edgar/data/1849296/000149315226004550/ex99-2.htm\n\nTrack it: https://pharmaconomics.com/e/1252
URL:https://pharmaconomics.com/e/1252
TRANSP:TRANSPARENT
BEGIN:VALARM
TRIGGER:-P1D
ACTION:DISPLAY
DESCRIPTION:OKYO catalyst tomorrow
END:VALARM
END:VEVENT
END:VCALENDAR